Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
SMD Rise PCL's Sloan Ratio for the quarter that ended in Mar. 2026 was 3.12%.
As of Mar. 2026, SMD Rise PCL has a Sloan Ratio of 3.12%, indicating the company is in the safe zone and there is no funny business with accruals.
SMD Rise PCL (BKK:SMD100-R) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, SMD Rise PCL has a Sloan Ratio of 3.12%, indicating the company is in the safe zone and there is no funny business with accruals.
SMD Rise PCL Sloan Ratio % Related Terms
SMD Rise PCL Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for SMD Rise PCL's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:SMD100-R vs MCK, CAH, COR: Sloan Ratio % Comparison
For the Medical Distribution subindustry, SMD Rise PCL's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SMD Rise PCL Sloan Ratio % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, SMD Rise PCL's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where SMD Rise PCL's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
SMD Rise PCL's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
SMD Rise PCL's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was -13.756 (Jun. 2025 ) + 29.244 (Sep. 2025 ) + 21.6 (Dec. 2025 ) + -30.544 (Mar. 2026 ) = ฿6.5 Mil.
SMD Rise PCL's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was 216.379 (Jun. 2025 ) + 105.783 (Sep. 2025 ) + -373.849 (Dec. 2025 ) + 77.57 (Mar. 2026 ) = ฿25.9 Mil.
SMD Rise PCL's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was -24.587 (Jun. 2025 ) + -11.457 (Sep. 2025 ) + -7.53 (Dec. 2025 ) + -19.085 (Mar. 2026 ) = ฿-62.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMD Rise PCL (BKK:SMD100-R) has a Sloan Ratio % of 3.12% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on SMD Rise PCL and its competitors.
Is SMD Rise PCL's Sloan Ratio % too high?
SMD Rise PCL's current Sloan Ratio % is 3.12%. Overall, SMD Rise PCL has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does SMD Rise PCL's Sloan Ratio % compare to MCK and CAH?
SMD Rise PCL's Sloan Ratio % of 3.12% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Distribution company?
A good Sloan Ratio % depends on the Medical Distribution industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on SMD Rise PCL and its competitors. SMD Rise PCL's current Sloan Ratio % is 3.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SMD Rise PCL stock overvalued right now?
SMD Rise PCL (BKK:SMD100-R) has a current Sloan Ratio % of 3.12%. The stock's GF Value™ is ฿24.10, compared to a current price of ฿5.85 — trading 75.7% below its estimated fair value. The current Sloan Ratio % is 3.12%. SMD Rise PCL's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For SMD Rise PCL (BKK:SMD100-R), the current Sloan Ratio % is 3.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SMD Rise PCL (BKK:SMD100-R) Overvalued in 2026?
Based on GuruFocus' analysis, SMD Rise PCL stock appears to be undervalued.
The current stock price of ฿5.85 is trading 75.7% below its estimated GF Value™ of ฿24.10.
Key valuation signals for BKK:SMD100-R:
Sloan Ratio %: 3.12%
GF Value™: ฿24.10 vs. price of ฿5.85 (75.7% below fair value)
No single metric tells the full story. See the BKK:SMD100-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Address222,222/1-2 Moo 1, Rattanathibet Road, West Inn Complex Building, 10th Floor, Bang Rak Yai Subdistrict, Bang Bua Thong District, Nonthaburi Province, Bangkok, THA, 11110
SMD Rise PCL, formerly Saintmed PCL is engaged in the import and distribution of medical devices and equipment, rental services for medical equipment, and providing services related to medical equipment. It operates in Thailand. The Group is engaged in three operating segments: Sale of medical devices and equipment, medical supplies, Services of medical equipment at sleep lab centers and repair services, and Revenue from rental of medical equipment at wellness centers and other services. The Group is managed and operates principally in Thailand.
60GF Score
Get the complete analysis for BKK:SMD100-R
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:SMD100-R has been successfully added to your 
